Serdep 50

Quick links to important sections

Serdep 50

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serdep 50

What is Serdep 50?

Serdep 50 is an oral medication that belongs to a class of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs). It is primarily used in the management of various mental health conditions characterized by imbalances in brain chemistry.

Composition and Mechanism

The active ingredient in Serdep 50 is sertraline hydrochloride. Each tablet contains 50 mg of this compound, which works by affecting the neurotransmitters in the brain. Neurotransmitters are chemical messengers that nerves use to communicate with one another.

Serotonin is one such neurotransmitter associated with mood, sleep, and emotional stability. Under normal conditions, serotonin is released by a nerve and then reabsorbed. In individuals experiencing certain psychological conditions, this balance may be disrupted. Serdep 50 functions by inhibiting the reabsorption (reuptake) of serotonin, thereby increasing the levels of active serotonin available in the synaptic gap between neurons. This process helps to enhance mood and emotional regulation.

Therapeutic Use

Serdep 50 is utilized to address several different psychological and emotional health concerns, including:

  • Major Depressive Disorder: Assisting in the relief of persistent feelings of sadness or loss of interest.
  • Panic Disorder: Helping to reduce the frequency and intensity of unexpected panic attacks.
  • Obsessive-Compulsive Disorder (OCD): Managing repetitive thoughts and behaviors.
  • Social Anxiety Disorder: Addressing the intense fear of social situations or performance.
  • Post-Traumatic Stress Disorder (PTSD): Assisting individuals in processing and managing symptoms following a traumatic event.

Unlike some other types of psychiatric medications, Serdep 50 is non-sedating for many users and is designed for long-term stabilization rather than immediate, short-term relief.

Regulatory References

  1. Sertraline (Zoloft) - MedlinePlus Drug Information

What side effects are possible with Serdep 50?

Possible Side Effects and Safety Information

The following information summarizes the official safety and adverse reaction profile of Sertraline (the active ingredient in Serdep 50), strictly as documented in governmental regulatory sources like the FDA and EMA. Adverse reactions are classified by the body system affected and their reported frequency in official labeling.


Classification of Common Adverse Reactions

Adverse reactions are formally grouped by the standard frequency categories used in regulatory documents:

  • Very Common Reactions (ge 1/10 patients): Reactions most frequently reported include Nausea, Insomnia, Dizziness, Somnolence, Diarrhea/Loose Stools, Dry Mouth, and, in males, Ejaculation Failure.
  • Common Reactions (ge 1/100 to <1/10 patients): These include Fatigue, Tremor, Decreased Appetite, Hyperhidrosis (increased sweating), Decreased Libido, and Dyspepsia.

Documented Serious Adverse Reactions and Safety Patterns

Regulatory agencies document specific serious and clinically significant safety concerns that require attention, often listed as Warnings and Precautions:

  • Serious Adverse Reactions: The potential for Serotonin Syndrome, Activation of Mania/Hypomania, Seizures, and Hyponatremia (low sodium levels) has been reported.
  • Suicidality Risk: Official labeling includes a warning concerning the increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults during the initial months of treatment.
  • Time-Related Patterns: Symptoms of Discontinuation Syndrome are common upon cessation, particularly if abrupt. Psychomotor Restlessness (Akathisia) is often noted as a concern during the first few weeks of therapy.
  • Safety Restrictions: Sertraline is contraindicated in individuals taking, or recently stopping, a Monoamine Oxidase Inhibitor (MAOI) and with concomitant use of Pimozide. Caution is advised for patients with a history of seizures or uncontrolled Angle-Closure Glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that overdosage with Serdep 50 (Sertraline) requires immediate medical attention and is managed primarily with supportive care. Documented overdose manifestations involve the central nervous system, cardiovascular system, and gastrointestinal system.

Documented Overdose Manifestations

Overdosage may present with symptoms including agitation, confusion, hallucinations, fever, sweating, and gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Neuromuscular signs may include shivering, severe muscle stiffness, and loss of coordination. Cardiovascular effects such as a rapid or irregular heartbeat have also been reported.

Severe Outcomes and Emergency Response

The official labeling notes the potential for seizures, coma (loss of consciousness), and signs of cardiotoxicity, including QRS and QTc interval prolongation. A severe risk is the development of Serotonin syndrome, which is more likely in a multiple drug overdosage involving other proserotonergic agents. Emergency services must be contacted immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Consultation with a Poison Center is also advised.

Official Management Approach

No specific antidote for Sertraline overdose is known. Management focuses on supportive symptomatic treatment. Regulatory guidance suggests that activated charcoal should be considered for gastrointestinal decontamination in patients presenting early.

Therapeutic Uses of Serdep 50

What Serdep 50 Treats: Main Uses and Benefits

Serdep 50 is commonly used across conditions presenting with acute episodes within recognized therapeutic domains. This medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, used in situations involving certain distressing symptoms such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD).

The medication helps address symptom clusters that may become intense or disruptive, such as profound sadness, overwhelming fear, persistent worry, and the loss of pleasure. It contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms create noticeable physiological strain.

“It provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

It is generally relevant when supportive symptom management is appropriate and commonly used when short-term symptomatic assistance is needed, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Fear and Worry
Serdep 50 is relevant for easing symptoms related to heightened physiological activity, assisting with functional stability in anxiety and panic spectrum disorders.

Regulatory References

  1. NIH clinical overview

Eligibility and Restrictions for Use

Serdep 50 (Sertraline) eligibility is determined by strict rules set forth in government regulatory labeling, categorizing populations as either allowed, restricted, or strictly prohibited from use.

Contraindicated Populations

Serdep 50 is absolutely contraindicated for patients with a known hypersensitivity to the medicine or its components, or for those taking, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI), including Linezolid. It must also not be used concomitantly with the medicine Pimozide.

Age-Related and Condition-Based Eligibility

Population Group Eligibility Status (Regulatory Wording)
Adults (18+ years) Permitted for all labeled indications.
Children (Under 6 years) Use is not established; safety and effectiveness data are absent.
Pediatric Patients (6–17 years) Approved only for Obsessive-Compulsive Disorder (OCD).
Severe Hepatic Impairment Not recommended for use.
Mild Hepatic Impairment Use requires caution; lower or less frequent dosing may be required.
Renal Impairment Permitted; dose adjustment is not required.

Use also requires caution in patients with a history of mania or unstable epilepsy. Pregnancy and lactation status is generally not recommended unless the clinical benefit outweighs the potential risk, as documented in the label.

What should I know about interactions with other medicines?

The official regulatory profile for Serdep 50 (Sertraline) defines specific medicinal combinations that are strictly prohibited due to interaction risks. Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, are formally contraindicated because co-administration significantly increases the risk of Serotonin Syndrome. A mandatory 14-day washout period must elapse both when stopping an MAOI before starting Serdep 50, and when stopping Serdep 50 before starting an MAOI. The antipsychotic Pimozide is also contraindicated, as Sertraline inhibits its metabolism, leading to increased plasma concentrations associated with a heightened risk of QTc prolongation.

Sertraline is a documented inhibitor of the CYP2D6 enzyme, a pharmacokinetic pattern that may increase the plasma exposure of co-administered CYP2D6 substrates, such as the Class 1C antiarrhythmics Propafenone and Flecainide. Pharmacodynamic interactions occur with other serotonergic agents like Triptans and the herbal medicine St. John's Wort, which can potentiate the risk of Serotonin Syndrome. Furthermore, co-administration with drugs that interfere with hemostasis, such as Warfarin or NSAIDs, increases the officially documented risk of bleeding. Regarding exposure, taking the tablet with food increases the maximum plasma concentration ( Cmax) by 25%. In the case of chronic mild liver impairment, Sertraline clearance is reduced, resulting in an approximately three-fold greater systemic exposure.

Mechanism of Action

Ontology: How Serdep 50 works — mechanism of action

Primary Mechanism: Serotonin Reuptake Inhibition

Serdep 50 (Sertraline) selectively blocks the Sodium-dependent Serotonin Transporter (SERT) protein on the presynaptic neuronal membrane, a mechanism that increases the concentration of the neurotransmitter serotonin (5-HT) available in the synaptic cleft. This engagement within the monoaminergic system modifies early molecular steps that influence subsequent neural signaling by altering signaling dynamics within the targeted pathways.

Cascades and Long-Term Synaptic Modulation

The sustained increase in synaptic serotonin initiates intracellular signaling sequences that lead to downstream effects, including the desensitization of autoreceptors and enhanced neurotrophic factor (BDNF) signaling. This mechanism involves processes that influence neural activity patterns, shaping the long-term adaptation of physiological responses associated with emotional processing.

Physiological Function Modulation

The overall action of Sertraline primarily occurs within the Central Nervous System (CNS), affecting circuits where specific transmitters dominate. This sustained influence on neural pathways involved in emotional responses and neuroplasticity alters the influence of excessive mediator activity, which initiates physiological adjustments that contribute to the drug’s overall pharmacodynamic effect profile.

Dosage and Administration Information

How to Use Serdep 50: Administration Principles

This section outlines the administration principles and dosing parameters for sertraline (Serdep 50), detailing the route of use, standard regimens, and required high-level usage contexts.


Administration Route and Frequency

The only approved route of administration for Serdep 50 is oral intake. The medicine is administered once daily, and the dose can be taken either in the morning or the evening. The tablet form may be administered with or without food.


Standard Labeled Dosing Regimens

Sertraline dosing typically begins with a specific starting dose followed by a gradual adjustment process called titration, up to a daily maximum of 200 mg for most approved uses.

Indication Initial Dose Maximum Daily Dose
Major Depressive Disorder, OCD 50 mg once daily 200 mg
Panic Disorder, PTSD, Social Anxiety 25 mg once daily, increased to 50 mg after 1 week 200 mg

Dose adjustments, when necessary, should occur at intervals of not less than one week. For Premenstrual Dysphoric Disorder (PMDD), continuous or intermittent dosing regimens (luteal phase only) are specified, with a maximum dose of 150 mg for continuous use.


Contextual and Procedural Instructions

Treatment discontinuation should be managed by a gradual dose reduction (tapering) whenever possible, to mitigate potential symptoms upon stopping therapy. If a dose is missed, it is advised to skip the missed dose and resume the regular schedule; a double dose should not be taken to compensate.

Special conditions apply to certain forms: the oral concentrate solution must be immediately diluted with specific liquids (e.g., water, orange juice) before being taken. Patients with hepatic impairment generally require a lower starting dose or less frequent dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Serdep 50

Evidence for Use in Major Depressive Disorder (MDD)

The research for conditions involving periods of heightened symptoms, such as Major Depressive Disorder, primarily relies on short-term randomized controlled trials (RCTs). These studies typically last between 8 and 12 weeks and were used to measure specific outcomes related to symptom evolution over time when compared against a placebo or other active treatments. The study populations included a range of adults, including older adults, and were also applied in studies examining patient-reported experiences in children and adolescents.

These studies monitored specific outcomes, such as the severity of depressive symptoms and changes in overall global clinical status (CGI). Studies monitored observed patterns in outcomes related to short-term changes during defined time intervals. Research highlights changes measured during the study period, contributing to the broader evidence landscape for MDD.

Evidence for Use in Anxiety, Panic, and Trauma Disorders

Research examined the medicine in conditions involving periods of heightened symptoms, including Panic Disorder, Posttraumatic Stress Disorder (PTSD), and Obsessive-Compulsive Disorder (OCD). Studies for these conditions used placebo-controlled trials to assess short-term or episodic symptom patterns and outcomes capturing phases of heightened symptom activity.

Studies for Obsessive-Compulsive Disorder (OCD)

For conditions characterized by fluctuating or episodic manifestations, such as OCD, the research includes short-term RCTs, typically lasting 10 to 12 weeks. Studies monitored outcomes related to the severity and frequency of obsessive and compulsive behaviors, using specialized scales. Research highlights changes measured during the study period, with long-term follow-up research describing patterns of symptom evolution during treatment periods extending over a year.

Studies for Panic Disorder and PTSD

Research for both Panic Disorder and PTSD was conducted using short-term placebo-controlled trials. Findings for PTSD were mixed across different study settings and patient cohorts. The research available is primarily derived from 12-week trials, meaning there is limited information for long-term outcomes and functional status beyond the short-term study periods.

What is Still Uncertain About the Serdep 50 Research Base

The evidence highlights what is known and what is still uncertain. Data for certain groups remain insufficient, and for some indications like PTSD, findings were mixed across specific patient cohorts. Follow-up durations were limited in many acute trials, meaning that long-term functional outcomes are not fully established. Comparative evidence is lacking for some specific patient subgroups and long-term recurrence evaluation. These research limitations mean that study results reflect the specific conditions under which they were conducted and provide context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Serdep 50 (FAQ)


Q: What is Serdep 50 actually used for?

Official documents list the approved indications for Serdep 50 (sertraline), which include Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).

It is also approved for treating specific anxiety-related conditions such as Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD).


Q: How quickly does Serdep 50 start working?

The medicine is not designed to work immediately. While individuals may notice some initial response within the first week, clinical study summaries generally indicate that the full therapeutic benefits often appear after several weeks.

This timeframe is typically described as between two to four weeks, or sometimes longer for certain conditions.


Q: Is Serdep 50 a benzodiazepine or habit-forming drug?

Serdep 50 (sertraline) is classified as a Selective Serotonin Reuptake Inhibitor (SSRI), and official documents state that it is not a benzodiazepine.

Furthermore, the official labeling states that the medicine has no abuse potential and is not associated with dependence. However, regulatory warnings mention that discontinuation symptoms can occur, especially if the medicine is stopped abruptly.


Q: Can Serdep 50 affect my ability to drive or operate machinery?

Official labeling includes a caution regarding potential side effects like dizziness or visual disturbance.

Official guidance includes a caution that individuals experiencing these symptoms should avoid driving or operating complex machinery.


Q: Are there known interactions between Serdep 50 and alcohol?

Regulatory documents state that use with alcohol should be avoided.

While studies have indicated that the medicine does not worsen the acute effects of alcohol, caution is still advised due to the potential for compounded central nervous system effects.


Q: Are headaches a common side effect of Serdep 50?

Headaches are documented as a very common side effect in the official product information for Serdep 50.

This means the official product information lists headaches as a 'very common' side effect, which is an effect that may affect many people.


Q: How does Serdep 50 affect mood in general?

Serdep 50 is described as working to modulate brain chemistry by increasing the functional availability of the neurotransmitter serotonin.

The overall purpose of this action, according to regulatory classification, is to support emotional balance and stabilize the brain circuits that regulate mood and psychological function.


Q: Can Serdep 50 affect blood pressure?

Side effects recorded in official sources sometimes include changes in blood pressure, specifically listing both hypertension (high blood pressure) and hypotension (low blood pressure).

This indicates that the medicine can potentially affect blood pressure in some individuals.


Q: Is Serdep 50 the same as other medicines like it?

Serdep 50, which contains sertraline, belongs to the pharmacological class known as a Selective Serotonin Reuptake Inhibitor (SSRI).

This classification means it has a highly selective action on the serotonin system, distinguishing it structurally from older or less selective classes of antidepressants.


Q: Can Serdep 50 change my appetite or weight?

Official product information lists decreased appetite as a common side effect of Serdep 50.

Additionally, adverse reactions related to changes in body weight, including both weight increase and weight decrease, have been reported as common or uncommon.


Q: Does Serdep 50 interact with commonly used over-the-counter pain relievers?

Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a common type of pain reliever, is noted in official documents to increase the risk of bleeding.

Regulatory information typically does not report a specific interaction for common pain relievers like acetaminophen (paracetamol).


Q: Is it common to feel worse right after starting Serdep 50?

The official warnings section describes the potential for symptoms such as anxiety, agitation, or psychomotor restlessness (akathisia) to occur or worsen during the first few weeks of therapy.

This information is included as a warning to provide context regarding possible initial changes.


Q: Does Serdep 50 have withdrawal symptoms when stopped?

Official documents describe the occurrence of a cluster of symptoms upon stopping treatment, referred to as a Discontinuation Syndrome.

Reported symptoms can include dizziness, sensory disturbances (paresthesia), sleep disturbances, agitation, and tremor.


Q: What types of allergic reactions are possible with Serdep 50?

Hypersensitivity reactions (allergic reactions) are listed as possible in the official adverse reaction data for Serdep 50.

Documented signs can range from common effects like rash and hives to more serious reactions like angioedema (swelling beneath the skin) or anaphylaxis.


Q: Can Serdep 50 affect liver function?

Serdep 50 is extensively metabolized (processed) by the liver. Due to this, severe hepatic impairment is listed as a contraindication in official product information.

Furthermore, effects such as hepatitis or elevations in liver enzymes have been reported as rare adverse reactions.


Q: How common are serious side effects from Serdep 50?

Official labeling focuses on detailing the full list of serious adverse reactions, such as Serotonin Syndrome or Seizures, due to their clinical importance.

However, the regulatory documentation typically does not provide an exact frequency for all serious events, focusing instead on describing their potential severity and required precautions.


Q: What are the risks of taking Serdep 50 with other psychiatric medications?

Co-administration with other serotonergic agents, a category that includes many psychiatric medicines, is noted to increase the risk of Serotonin Syndrome.

Interactions may also occur with medicines that are metabolized by the CYP2D6 enzyme pathway.


Q: Can men experience specific side effects from Serdep 50?

Official documentation lists specific side effects more prevalent in men, such as ejaculation failure, which is noted as a very common reaction.

Decreased libido (sexual dysfunction) is also commonly reported.


Q: Can women experience specific side effects from Serdep 50?

Official documents list female sexual dysfunction as a common side effect in women.

Other documented reactions affecting the reproductive system, such as menstrual cycle irregularity, have been listed as uncommon or rare.


Q: Does Serdep 50 interact with birth control pills?

Official regulatory documents typically state that Sertraline does not affect the efficacy of hormonal contraceptives, such as birth control pills.


Q: Can Serdep 50 make my periods irregular?

Adverse reaction lists sometimes include changes to the reproductive system.

Official information suggests that menstrual cycle irregularity or menorrhagia (heavy bleeding) have been reported as uncommon or rare side effects of the medicine.


Q: Is Serdep 50 prescribed to people who have anxiety?

Official labeling states the medicine is approved for the treatment of specific anxiety-related disorders.

These approved conditions include Panic Disorder, Social Anxiety Disorder (SAD), and Posttraumatic Stress Disorder (PTSD).


Q: Does Serdep 50 have different effects on men and women?

Official information confirms sex-based differences in the prevalence of certain side effects (e.g., sexual dysfunction symptoms differ between sexes) and differences in the pharmacokinetics (how the body processes the drug) have been noted.


Q: Are there any specific foods or drinks that should be avoided with Serdep 50?

Regulatory documents identify co-administration with MAOIs (including Linezolid and IV Methylene Blue) and the antipsychotic Pimozide as contraindications (absolute restrictions).

Official documents also state that use with alcohol should be avoided.


How should Serdep 50 be stored and disposed of?

Official Storage and Disposal Requirements

Serdep 50 (sertraline tablets) must be stored according to regulatory specifications to maintain product integrity and ensure safety. Storage is required at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, with the cap tightly closed, and stored away from excess heat, moisture, and freezing temperatures. All medications must be secured out of the sight and reach of children.

Disposal of unused or expired Serdep 50 should primarily utilize an authorized drug take-back program. If a program is unavailable, tablets can be mixed with an undesirable substance (e.g., coffee grounds) in a sealed bag and placed in the household trash. The medication must not be flushed down the toilet or thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Serdep 50 found in:

A-Z Index: